Increase in cases of bipolar disorders coupled by speedy approval of drugs pertaining to them are responsible for boosting the bipolar disorder treatment market revenue. Bipolar disorder is amongst the serious mental illnesses that result in severe and unusual mood alterations.
The episodes of ‘highs’ and ‘lows’ may switch rapidly in a week. Psychotic symptoms such as delusions or hallucinations and thoughts of suicide or self-harm are also observed.
The companies operating in bipolar disorder treatment market are conducting research regarding response of the individual to mood stabilizers (MS), antidepressants (AD), and antipsychotics (AP) to check if familial-genetic risk is the major influencer over here. The inferences are expected to help in devising new drugs in this regard.
Bipolar disorder means a disorder linked with episodes of mood swings between depressive lows and manic highs.
The actual cause of bipolar disorder is not known, but an amalgamation of genetics, surroundings, and altered chemistry and brain structure are likely to play a role.
Manic episodes could include symptoms such as sleeplessness and losing touch with the reality. Episodes of depression may include the symptoms such as low motivation, low energy, and losing interest in daily activities. The mood episodes may, at times, be linked to suicidal thoughts as well.
Bipolar disorder treatment is generally a prolonged process and generally involves combining psychotherapy and medications.
However, certain drugs used for treating bipolar disorders are likely to alter the way the body functions if used longer than required. Lithium, as a mood stabilizer, may adversely affect organs such as kidneys. These factors may restrain the bipolar disorder treatment market in the near future.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the WHO, more than 45 million individuals worldwide are suffering from bipolar disorder.
Though bipolar disorder falls in the category of non communicable diseases, at one point, a set of individual, community, family, and structural factors may combine in order to undermine the mental health.
Majority of people turn out to be resilient, but those exposed to the adverse circumstances such as poverty, disability, violence, and inequality are at a higher risk.
The WHO further states that health systems haven’t responded well to requirements of people contracting mental disorders and are also under resourced on a significant count. That’s why, merely 33% of the ones suffering from depression receive official mental health care.
Need to apprise individuals about various types of mental disorders including bipolar disorder is thus expanding bipolar disorder treatment market size.
Quick approvals for bipolar disorder treatment by regulatory bodies is encouraging the demand for mood disorder therapy. For instance, in May 2021, Alembic Pharmaceuticals received approval from the U.S. FDA for Lurasidone Hydrochloride tablets that are used for treating bipolar depression.
In December 2021, Intra-Cellular Therapies, Inc. confirmed that the U.S. FDA had approved CAPLYTA to treat depressive episodes linked with bipolar I or II disorder in the adults, such as monotherapy and adjunctive therapy with valproate or lithium.
In December 2020, NeuroRx, Inc. inked an agreement with Big Rock Partners Acquisition Corp. in order to increase devising new therapeutics to treat bipolar depression and Covid-19.
In September 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck announced that the U.S. FDA had approved their new drug application (NDA) for a 2-month medication for schizophrenia and bipolar disorder I in adults. It is called ‘aripiprazole’.
Research regarding introduction of CaMKK2 that enrich brain neurons and regulate neuronal processes is on.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America held the largest bipolar disorder treatment market share in 2023 and the scenario is expected to remain unchanged during the forecast period. This is attributed to rise in the cases of bipolar disorder in the U.S. As per the report published by the National Alliance on Mental Illness, 20% of adults in the U.S. experience mental illness every year.
It further states that bipolar I disorder in characterized by manic symptoms that are severe to the extent of the patient needing hospital care with immediate effect.
Asia Pacific’s significant bipolar disorder treatment market growth is due to rising awareness about the need to identify and treat mental disorders in India and China. Asia Pacific Economic Cooperation (APEC) is nurturing the Healthy Asia Pacific 2020 Initiative organized in 2014.
The bipolar disorder treatment market manufacturers are launching new products followed by speedy approvals by the regulatory authorities. For instance, in April 2022, BioXcel Therapeutics, Inc. announced that its IGALMI (dexmedetomidine) sublingual film was approved by the U.S. FDA for treatment of acute bipolar I or II disorder in the adults.
The bipolar disorder treatment market report highlights Otsuka Pharmaceutical Co., Ltd., AstraZeneca plc, GSK plc, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Novartis AG, Allergan plc, and Lundbeck A/S based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 5.1 Bn |
| Market Forecast (Value) in 2034 | US$ 9.2 Bn |
| Growth Rate (CAGR) | 5.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 5.1 Bn in 2023
It is projected to grow at a CAGR of 5.4% from 2024 to 2034
Growing prevalence of bipolar disorder and speedy approvals of therapeutics by regulatory authorities
Hospitals segment accounted for the largest share in 2023
North America was the dominant region in 2023
Otsuka Pharmaceutical Co., Ltd., AstraZeneca plc, GSK plc, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Novartis AG, Allergan plc, and Lundbeck A/S
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Bipolar Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bipolar Disorder Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Bipolar Disorder Treatment Market Analysis and Forecast, by Type of Treatment
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Treatment, 2020-2034
6.3.1. Pharmacotherapy
6.3.2. Psychotherapy
6.3.3. Electroconvulsive Therapy (ECT)
6.3.4. Transcranial Magnetic Stimulation (TMS)
6.3.5. Others (Hospitalization, etc.)
6.4. Market Attractiveness, by Type of Treatment
7. Global Bipolar Disorder Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2020-2034
7.3.1. Mood Stabilizers
7.3.2. Antipsychotics
7.3.3. Anti-depressants
7.3.4. Antianxiety Drugs
7.3.5. Others (Anticonvulsants, etc.)
7.4. Market Attractiveness, by Drug Class
8. Global Bipolar Disorder Treatment Market Analysis and Forecast, by Type of Bipolar Disorder
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
8.3.1. Bipolar I Disorder
8.3.2. Bipolar II Disorder
8.3.3. Cyclothymic Disorder
8.3.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
8.4. Market Attractiveness, by Type of Bipolar Disorder
9. Global Bipolar Disorder Treatment Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Mental Health Centers
9.3.4. Ambulatory Surgical Centers
9.4. Market Attractiveness, by End-user
10. Global Bipolar Disorder Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Bipolar Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Treatment, 2020-2034
11.2.1. Pharmacotherapy
11.2.2. Psychotherapy
11.2.3. Electroconvulsive Therapy (ECT)
11.2.4. Transcranial Magnetic Stimulation (TMS)
11.2.5. Others (Hospitalization, etc.)
11.3. Market Attractiveness, by Type of Treatment
11.4. Market Value Forecast, by Drug Class, 2020-2034
11.4.1. Mood Stabilizers
11.4.2. Antipsychotics
11.4.3. Anti-depressants
11.4.4. Antianxiety Drugs
11.4.5. Others (Anticonvulsants, etc.)
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
11.6.1. Bipolar I Disorder
11.6.2. Bipolar II Disorder
11.6.3. Cyclothymic Disorder
11.6.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
11.7. Market Attractiveness, by Type of Bipolar Disorder
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Mental Health Centers
11.8.4. Ambulatory Surgical Centers
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type of Treatment
11.11.2. By Drug Class
11.11.3. By Type of Bipolar Disorder
11.11.4. By End-user
11.11.5. By Country
12. Europe Bipolar Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Treatment, 2020-2034
12.2.1. Pharmacotherapy
12.2.2. Psychotherapy
12.2.3. Electroconvulsive Therapy (ECT)
12.2.4. Transcranial Magnetic Stimulation (TMS)
12.2.5. Others (Hospitalization, etc.)
12.3. Market Attractiveness, by Type of Treatment
12.4. Market Value Forecast, by Drug Class, 2020-2034
12.4.1. Mood Stabilizers
12.4.2. Antipsychotics
12.4.3. Anti-depressants
12.4.4. Antianxiety Drugs
12.4.5. Others (Anticonvulsants, etc.)
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
12.6.1. Bipolar I Disorder
12.6.2. Bipolar II Disorder
12.6.3. Cyclothymic Disorder
12.6.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
12.7. Market Attractiveness, by Type of Bipolar Disorder
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Mental Health Centers
12.8.4. Ambulatory Surgical Centers
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type of Treatment
12.11.2. By Drug Class
12.11.3. By Type of Bipolar Disorder
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Bipolar Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Treatment, 2020-2034
13.2.1. Pharmacotherapy
13.2.2. Psychotherapy
13.2.3. Electroconvulsive Therapy (ECT)
13.2.4. Transcranial Magnetic Stimulation (TMS)
13.2.5. Others (Hospitalization, etc.)
13.3. Market Attractiveness, by Type of Treatment
13.4. Market Value Forecast, by Drug Class, 2020-2034
13.4.1. Mood Stabilizers
13.4.2. Antipsychotics
13.4.3. Anti-depressants
13.4.4. Antianxiety Drugs
13.4.5. Others (Anticonvulsants, etc.)
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
13.6.1. Bipolar I Disorder
13.6.2. Bipolar II Disorder
13.6.3. Cyclothymic Disorder
13.6.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
13.7. Market Attractiveness, by Type of Bipolar Disorder
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Mental Health Centers
13.8.4. Ambulatory Surgical Centers
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type of Treatment
13.11.2. By Drug Class
13.11.3. By Type of Bipolar Disorder
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Bipolar Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Treatment, 2020-2034
14.2.1. Pharmacotherapy
14.2.2. Psychotherapy
14.2.3. Electroconvulsive Therapy (ECT)
14.2.4. Transcranial Magnetic Stimulation (TMS)
14.2.5. Others (Hospitalization, etc.)
14.3. Market Attractiveness, by Type of Treatment
14.4. Market Value Forecast, by Drug Class, 2020-2034
14.4.1. Mood Stabilizers
14.4.2. Antipsychotics
14.4.3. Anti-depressants
14.4.4. Antianxiety Drugs
14.4.5. Others (Anticonvulsants, etc.)
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
14.6.1. Bipolar I Disorder
14.6.2. Bipolar II Disorder
14.6.3. Cyclothymic Disorder
14.6.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
14.7. Market Attractiveness, by Type of Bipolar Disorder
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Mental Health Centers
14.8.4. Ambulatory Surgical Centers
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type of Treatment
14.11.2. By Drug Class
14.11.3. By Type of Bipolar Disorder
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Bipolar Disorder Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Treatment, 2020-2034
15.2.1. Pharmacotherapy
15.2.2. Psychotherapy
15.2.3. Electroconvulsive Therapy (ECT)
15.2.4. Transcranial Magnetic Stimulation (TMS)
15.2.5. Others (Hospitalization, etc.)
15.3. Market Attractiveness, by Type of Treatment
15.4. Market Value Forecast, by Drug Class, 2020-2034
15.4.1. Mood Stabilizers
15.4.2. Antipsychotics
15.4.3. Anti-depressants
15.4.4. Antianxiety Drugs
15.4.5. Others (Anticonvulsants, etc.)
15.5. Market Attractiveness, by Drug Class
15.6. Market Value Forecast, by Type of Bipolar Disorder, 2020-2034
15.6.1. Bipolar I Disorder
15.6.2. Bipolar II Disorder
15.6.3. Cyclothymic Disorder
15.6.4. Others (Specified and Unspecified Bipolar and Related Disorders, etc.)
15.7. Market Attractiveness, by Type of Bipolar Disorder
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Mental Health Centers
15.8.4. Ambulatory Surgical Centers
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type of Treatment
15.11.2. By Drug Class
15.11.3. By Type of Bipolar Disorder
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Otsuka Pharmaceutical Co., Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. AstraZeneca plc
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GSK plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Eli Lilly and Company
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Johnson & Johnson
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. AbbVie Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Novartis AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Allergan plc
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Lundbeck A/S
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 02: Global Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 03: Global Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 05: Global Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 08: North America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 09: North America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 10: North America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 13: Europe Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 14: Europe Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 15: Europe Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 18: Asia Pacific Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 19: Asia Pacific Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 20: Asia Pacific Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 23: Latin America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 24: Latin America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 25: Latin America Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Treatment, 2020-2034
Table 28: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 29: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by Type of Bipolar Disorder, 2020-2034
Table 30: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Bipolar Disorder Treatment Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Bipolar Disorder Treatment Market Revenue (US$ Bn), by Type of Treatment, 2023
Figure 03: Global Bipolar Disorder Treatment Market Value Share, by Type of Treatment, 2023
Figure 04: Global Bipolar Disorder Treatment Market Revenue (US$ Bn), by Drug Class, 2023
Figure 05: Global Bipolar Disorder Treatment Market Value Share, by Drug Class, 2023
Figure 06: Global Bipolar Disorder Treatment Market Revenue (US$ Bn), by Type of Bipolar Disorder, 2023
Figure 07: Global Bipolar Disorder Treatment Market Value Share, by Type of Bipolar Disorder, 2023
Figure 08: Global Bipolar Disorder Treatment Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global Bipolar Disorder Treatment Market Value Share, by End-user, 2023
Figure 10: Global Bipolar Disorder Treatment Market Value Share, by Region, 2023
Figure 11: Global Bipolar Disorder Treatment Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 13: Global Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 14: Global Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 15: Global Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 16: Global Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 17: Global Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 18: Global Bipolar Disorder Treatment Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global Bipolar Disorder Treatment Market Value Share, by End-user, 2023
Figure 20: Global Bipolar Disorder Treatment Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Bipolar Disorder Treatment Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Bipolar Disorder Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Bipolar Disorder Treatment Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Bipolar Disorder Treatment Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 26: North America Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 27: North America Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 28: North America Bipolar Disorder Treatment Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 30: North America Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 31: North America Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 32: North America Bipolar Disorder Treatment Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Bipolar Disorder Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Bipolar Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Bipolar Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 37: Europe Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 38: Europe Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 39: Europe Bipolar Disorder Treatment Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 41: Europe Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 42: Europe Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 43: Europe Bipolar Disorder Treatment Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Bipolar Disorder Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Bipolar Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Bipolar Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 48: Asia Pacific Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 49: Asia Pacific Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 50: Asia Pacific Bipolar Disorder Treatment Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 52: Asia Pacific Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 53: Asia Pacific Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 54: Asia Pacific Bipolar Disorder Treatment Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Bipolar Disorder Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Bipolar Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Bipolar Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 59: Latin America Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 60: Latin America Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 61: Latin America Bipolar Disorder Treatment Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 63: Latin America Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 64: Latin America Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 65: Latin America Bipolar Disorder Treatment Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Bipolar Disorder Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Bipolar Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Bipolar Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Bipolar Disorder Treatment Market Value Share Analysis, by Type of Treatment, 2023 and 2034
Figure 70: Middle East & Africa Bipolar Disorder Treatment Market Value Share Analysis, by Drug Class, 2023 and 2034
Figure 71: Middle East & Africa Bipolar Disorder Treatment Market Value Share Analysis, by Type of Bipolar Disorder, 2023 and 2034
Figure 72: Middle East & Africa Bipolar Disorder Treatment Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Treatment, 2024-2034
Figure 74: Middle East & Africa Bipolar Disorder Treatment Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 75: Middle East & Africa Bipolar Disorder Treatment Market Attractiveness Analysis, by Type of Bipolar Disorder, 2024-2034
Figure 76: Middle East & Africa Bipolar Disorder Treatment Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Bipolar Disorder Treatment Market
